{
    "NCTID": "NCT00123456",
    "trial_id": "Yleg6i4pOxyjcqCleKDa",
    "phase": "Phase I",
    "title": "Safety and Efficacy Study of Lonafarnib in Hutchinson-Gilford Progeria Syndrome",
    "brief_summary": "A phase I study evaluating the safety, tolerability, and preliminary efficacy of lonafarnib in children with Progeria.",
    "drug": "Lonafarnib",
    "description": "This study aims to determine the maximum tolerated dose of lonafarnib and observe its effects on cardiovascular and metabolic parameters in patients with Hutchinson-Gilford Progeria Syndrome.",
    "disease_targeted": "Hutchinson-Gilford Progeria Syndrome",
    "inclusion_criteria": [
      { "criterion": "Age between 3 and 12 years." },
      { "criterion": "Confirmed diagnosis of Hutchinson-Gilford Progeria Syndrome." }
    ],
    "exclusion_criteria": [
      { "criterion": "Presence of severe renal impairment." },
      { "criterion": "Concurrent participation in another clinical trial." }
    ],
    "enrollment_capacity": 30,
    "sponsor": "Progeria Research Foundation",
    "locations": [
      {
        "location_id": "LOC1001",
        "address": "123 Research Blvd",
        "city": "Boston",
        "state": "MA",
        "country": "USA"
      }
    ],
    "start_date": "2025-05-01T00:00:00Z",
    "end_date": "2026-05-01T00:00:00Z",
    "status": "recruiting",
    "contact_info": {
      "phone": "+1-617-555-0101",
      "email": "info@progeriaresearch.org",
      "website": "https://www.progeriaresearch.org"
    },
    "data_security_details": "All patient data is encrypted and access is controlled via multi-factor authentication in accordance with HIPAA.",
    "study_results": [],
    "adverse_events": [],
    "created_at": "2025-03-02T12:00:00Z",
    "updated_at": "2025-03-02T12:00:00Z",
    "additional_comments": [
      "Initial trial setup completed.",
      "Patient recruitment ongoing."
    ],
    "matching_criteria": [
      "genetic mutation LMNA",
      "cardiovascular health markers"
    ]
  }
  